| Hazard Information | Back Directory | [Uses]
BTG 1640 (ABIO-08/01) is a potent anxiolytic isoxazoline. BTG 1640 is a selective inhibitor of GABA- and glutamate-gated chloride channels[1]. | [in vivo]
BTG 1640 (ABIO-08/01) displays an activity at a very low dosage after single intraperitoneal and single oral administration (gavage) in mouse and rat models of anxiety. Chronic administration resulted neither in tolerance development nor in withdrawal symptoms after abrupt discontinuation of treatment (data on file)[2]. | [References]
[1] Correll CU, et al. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents. World Psychiatry. 2023 Feb;22(1):48-74. DOI:10.1002/wps.21056
[2] Saletu-Zyhlarz GM, et al. Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 1. EEG mapping, psychometric and tolerability findings. Neuropsychobiology. 2009;59(2):100-9. DOI:10.1159/000212379 |
|
|